ArticleScientific reports2026
Key hub genes identification and therapeutic target prediction via multi-validation for the senescence-inflammation axis in prostate cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular senescence remodels the microenvironment via SASP, and immune inflammation promotes carcinogenesis through DNA damage and immune remodeling; the “senescence-inflammation” vicious cycle formed by these two processes is a core driver of cancer development and progression, yet its mechanism in prostate cancer progression remains unclear. The regulatory mechanisms of “senescence-inflammation” related genes in prostate cancer were revealed, targeted drugs were predicted, and new insights were provided for the clinical treatment of prostate cancer. In this study, gene expression profile data of prostate cancer were obtained from the Gene Expression Omnibus (GEO). Differentially expressed genes were screened out through bioinformatics analysis and verified by experiments; GO and KEGG analyses were used to explore the prostate cancer-specific biological processes and signaling pathways involved, immune infiltration characteristics were revealed by combining immune infiltration tools with single-cell technology, and finally, drugs with therapeutic potential were predicted through core gene target analysis. Prostate cancer-related differentially expressed genes were found to number 203. Notable hub genes included ACTB, RPLP0, TOP2A, TXN, HSP90B1, TAGLN, RPSA, and ANXA2. According to enrichment analysis, apoptosis, cellular senescence, inflammation, and the initiation of immunological responses are the main factors contributing to the development of bladder cancer. The immunological processes of prostate cancer are significantly influenced by memory B cells, CD8 T cells, follicular helper T cells, M1 macrophages, monocytes, and NK cells, as confirmed by immune infiltration and single-cell data. Furthermore, hub genes were found to be significantly expressed in a variety of immune cells by single-cell studies; monocytes and macrophages in particular exhibited high levels of ACTB, RPLP0, RPSA, and ANXA2. We next used Western blotting, PCR, and immunohistochemistry to evaluate these genes’ expression in clinical samples. Lastly, Miconazole, Fostamatinib, Quercetin, Resveratrol, and Regorafenib were shown to be possible important drugs or ingredients for the treatment of prostate cancer by our drug-target interaction prediction analysis. We clarified the mechanism by which immune-inflammatory and aging-related genes contribute to the pathogenesis of prostate cancer. We identified and validated four core genes, namely TXN, TOP2A, ANXA2, and HSP90B1, and predicted potential therapeutic agents, specifically resveratrol and regorafenib. These findings provide a theoretical basis for research on the molecular mechanisms of prostate cancer and its clinical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.